In the current study we describe the enhanced anti-tumor activity of the dual PI3K/mTOR inhibitor PF-502 and the MEK inhibitor PD-901 in in vitro and in vivo models of colorectal cancer. Here, MAP2K7 is linked to colorectal cancer.